Please login to the form below

Not currently logged in
Email:
Password:

Large antibody order for AbD Serotec

Proteomika SL has placed a large order for multi research antibodies with MorphoSys AG's AbD Serotec business unit.

Proteomika SL has placed a large order for multi research antibodies with MorphoSys AG's AbD Serotec business unit.

The Spanish biotech company, which specialises in biomarker technology, will be taking advantage of MorphoSys AG's HuCAL Gold (a powerful antibody library) based novel research antibodies.

This order will rank Proteomika, which is actively involved in cancer research/discovery programmes, as one of MorphoSys AG's largest customers

Dr Simon Moroney, CEO of MorphoSys AG, said: "This order is one of the largest generated by AbD Serotec, and highlights the advantage of our HuCAL technology in bespoke proteomics applications.

"We welcome the decision of Proteomika to use HuCAL Gold research antibodies in its proteomics programs."

A subsidiary of Progenika Biopharma SA, Proteomika was set up to exploit advances in biomarker research for the development of diagnostic and prognostic products.

Since its creation in 2002, the firm has established research collaborations with pharma and biotech companies aiming to validate non-invasive diagnostic and pharmacoproteomics.

Dr Laureano Simon, CEO of Proteomika, said: "The fast turn around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of biomarker identification and validation."

Neither company involved in the deal has released financial details of the agreement.

5th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics